Tillkännagivande • May 02
Nymox Pharmaceutical Corporation announced delayed 20-F filing On 05/01/2025, Nymox Pharmaceutical Corporation announced that they will be unable to file their next 20-F by the deadline required by the SEC. Tillkännagivande • Mar 27
Nymox Pharmaceutical Corporation Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages Nymox Pharmaceutical Corporation reported that the Bahamas Supreme Court has issued a formal Order officially putting an end to the Bahamas litigation brought by terminated ex-employees. The Order also awards to Nymox its costs incurred in defending the ill-conceived lawsuit, as well as damages Nymox has suffered as a result of the litigation. The Court order states the following: The Interim Injunction Order is set aside; The damages caused to the Company shall be assessed by a Registrar and paid by the Claimants (the persons who filed the lawsuit); and The Claimants shall pay the Company’s net costs for the entire Action. This is the first of more than one action by and between the Company and Randall Lanham, (former General Counsel for Nymox), Chris Riley, (former short-term CFO), Richard Cutler (former external Counsel and member of Board), and their financial backers. Tillkännagivande • Sep 26
Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH Nymox Pharmaceutical Corporation announced that a new formal submission has been made by the company in the U.K. for Nymozarfex (TM) for the treatment of benign prostatic hyperplasia (BPH). The Marketing Authorization Application (MAA) was submitted to the U.K. Medicines & Healthcare products Regulatory Agency (MHRA). The new submission includes England, Wales, Scotland and Northern Ireland. The company will provide further information, including with respect to other submissions for Nymozarfex (TM), when the information becomes available. Tillkännagivande • Sep 08
The Nasdaq Stock Market to Delist the Common Stock of Nymox Pharmaceutical The Nasdaq Stock Market announced that it will delist the common stock of Nymox Pharmaceutical Corporation. Nymox Pharmaceutical Corporation’s securities were suspended on July 7, 2023, and have not traded on Nasdaq since that time. Tillkännagivande • Aug 03
Nymox Pharmaceutical Corporation announced that it expects to receive $2 million in funding Nymox Pharmaceutical Corporation announced a private placement of 2,000,000 common shares at a price of $1.00 per share for gross proceeds of $2,000,000 on August 2, 2023. The company will also issue 500,000 warrants. The transaction included participation from James G. Robinson, an independent director of the company. The investment will close in the upcoming days after the customary formalities are completed. Tillkännagivande • Jul 26
Nymox Pharmaceutical Corporation Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results Nymox Pharmaceutical Corporation announced important new long-term clinical trial results from the company's 146 patient NX03-0040 NYMOZARFEX (TM) U.S. study for low grade localized prostate cancer. New long-term follow-up data from the prospective randomized clinical trial of NYMOZARFEX (TM) for low grade early prostate cancer has indicated that there is strong statistically significant benefit from the treatment compared to controls when all available patient outcomes were included from 18 months to as long as up to >10 years after treatment. These additional 5 to 10-year data points add to the 5-year data that was published in the peer review World Journal of Urology in 2020 (World J Urol 38, 3101–3111 (2020). All clinical trial sites that were still open were contacted for follow-up data on the prostate cancer status of all available patients. A full effort was made to reach all possible subjects. The outcome comparisons showed greatly reduced percentages of subjects treated with NYMOZARFEX (TM) who had progressed by either cancer grade worsening or by prostate cancer surgery, radiotherapy, or chemotherapy; and which remained overall strongly statistically significant compared to the study's randomized controls (p<.01). This unique and successful study is the world's first and only long-term prospective randomized controlled study of an intraprostatic molecular injectable treatment for low-grade localized prostate cancer to have been accomplished. The new data represents the longest term data available from this major study. Study NX03-0040 was undertaken starting in 2012 at investigational sites across the U.S. with 146 men with the biopsy confirmed diagnosis of Grade Group1 prostate cancer. NYMOZARFEX (TM) was administered by a single painless injection directly into the prostate in a relatively simple procedure requiring several minutes or less in an office setting without sedation or anesthesia, and guided by routine ultrasound. NYMOZARFEX (TM) was injected into the area of the prostate where the cancer was previously detected prior to enrollment in NX03-0040. The patients were then biopsied after 6 weeks and then every 18 months, along with serial PSA measurements and long-term follow-up. All subjects with 18 months or more follow-up were compared with the inclusion of follow-up data from up to 10 years or more after a single injection of NYMOZARFEX (TM). For the patients where investigational sites were closed or where patients for unrelated reasons were no longer available, the last known status reports were included if they were 18 months or longer. For any subject with a worsening (increase) in grade of prostate cancer on biopsy; or with prostate cancer surgery, or radiotherapy or chemotherapy, they were included regardless of time after study treatment, and were counted in the calculation as treatment failures. The data shows that the number of patients with one focal injection of NYMOZARFEX (TM) 15 mg directed at the tumor had significantly less progression to more advanced cancer or to major cancer treatments, than the randomized control subjects followed in the study. Low grade localized prostate cancer (Gleason 3+3; T1c) is a very common treatment problem. The Nymox study reported involves patients with initially Gleason grade 3+3 or lower. These patients are found to have these tumors by biopsy which is usually instituted after finding abnormalities in PSA levels, and/or after abnormal digital rectal examination of the prostate, and/or after the patient has experienced lower urinary tract symptoms or other changes. Low grade localized prostate cancer represents a therapeutic challenge. Because of its slow growth and low initial level of malignancy, urologists and patients can be reluctant to proceed to invasive surgical treatments or radiotherapy due to the unpleasant and often permanent side effects these treatments cause in the genitourinary tract, such as sexual functional issues and/or urinary issues. Eventually if and when the tumor progresses, invasive surgical and/or radiotherapeutic procedures become necessary, with greater risk due to the progression. Occasionally the tumors become highly malignant after variable lengths of time. These risks cause understandable anxieties and distress and many men prefer to advance to invasive therapy before running these risks of higher grade cancers. It is widely acknowledged that a treatment like NYMOZARFEX (TM) that can destroy or ablate the low grade cancers of the prostate without the dreaded side effects and morbidities, would be an important benefit for these patients. Prostate cancer is the most commonly diagnosed cancer in men, other than skin cancer, and is the second leading cause of cancer death for men. Approximately 50% of prostate cancers are initially considered low risk. One of the major problems with the main current prostate treatments for localized prostate cancer (radical prostatectomy, external beam radiation, brachytherapy) is the relatively high incidence of serious sexual and other problems post- treatment. In 9 studies, NYMOZARFEX (TM) treatment has been shown to have a negligible significant adverse effect profile post-treatment and no significant adverse effects on sexual or other functions or testosterone levels. Leading urologists have long recognized the unmet need for prostate cancer treatments that can contribute to improved outcomes for their patients together with reduced side effects and stresses that may have significantly impact on quality of life. The goal of NYMOZARFEX (TM) injectable is to allow for an initial and less toxic treatment for low-risk prostate cancer patients, achieving the benefits of molecular ablation with minimal risk of side effects. For many patients, this treatment combined with surveillance would be extremely helpful for the unpleasant and persistent uncertainties, anxieties, and psychological/emotional burdens associated with only selecting active surveillance. Tillkännagivande • Jul 13
Nymox Pharmaceutical Corporation Appoints Patrick Doody as Vice President, General Counsel and Member of Board of Directors Nymox Pharmaceutical Corporation announced the appointment of Patrick Doody as Vice President, General Counsel, and Member of Board of Directors. Mr. Doody joins Nymox from Pillsbury Winthrop Shaw Pittman LLP, where he was a partner in the Intellectual Property Group, and currently is Senior Counsel. Mr. Doody is a well-respected patent attorney with significant knowledge and experience in post-grant proceedings, patent infringement litigation, patent prosecution, licensing, opinions, and counseling. Mr. Doody has represented Nymox and its predecessor company in intellectual property matters for over 30 years, securing hundreds of issued patents for Nymox throughout the world. Mr. Doody is a former patent examiner, former in-house counsel for Union Carbide Corporation, former partner at Tier 1, AMLAW 100 firms, and also is an adjunct professor of patent law at the George Washington University School of Law. Mr. Doody obtained his BS degree in Chemical Engineering from Virginia Tech, and his law degree from the Scalia School of Law (formerly George Mason School of Law), has served in a number of leadership positions in various intellectual property associations, is ranked Band 2 by Chambers for Intellectual Property, and AV ranked by Martindale Hubbell. Much of Mr. Doodys legal career has involved counseling biotechnology, pharmaceutical, and chemical companies on all aspects of intellectual property law. Tillkännagivande • Jul 06
Nymox Delisting from NASDAQ Nymox Pharmaceutical Corporation (the “Company”) received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company's shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023. Nymox shares will be moved to the OTC market. The mechanics of trading the stock remain the same, as do the Company's business fundamentals. Nymox is in the process of submitting applications for the approval to market the Company's first in class drug NYMOZARFEX to treat the symptoms of benign prostatic hyperplasia (BPH). BPH is one of the most common conditions affecting middle aged and elderly men throughout the world. BPH can be devastating to men who suffer from the condition. Current treatments are associated with numerous intolerable side effects including sexual problems, such as impotence and retrograde ejaculation. Medications for BPH have been associated with prostate cancer, depression, gynecomastia and other adverse effects. The majority of men stop taking the available medications due to these and other problems. Surgery is often needed for advanced BPH. Surgery is usually effective but it is not without risks, the discomforts of surgery, and BPH surgery has side effects such as permanent retrograde ejaculation for many patients. Nymozarfex was submitted to the Danish authorities in December 2022 and the application was accepted for review in early 2023 and is currently undergoing review. The Company announced that another submission was expected to be submitted for approval in another jurisdiction in the second quarter of 2023. It is expected to be submitted in the near future and the Company will provide the appropriate update when that occurs. New Risk • Jul 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.0m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$1.8m). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$17.3m market cap). Tillkännagivande • Dec 06
Nymox Pharmaceutical Corporation Announces New Marketing Submission for Nymozarfex for BPH Nymox Pharmaceutical Corporation announced that a new formal submission has been made by the Company in Europe for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH). The trademarked name for the product in the application is NYMOZARFEX (TM). The Marketing Authorization Application (MAA) was submitted to the Danish authorities. The Company will provide further information, including other expected submissions, when the information becomes available. Tillkännagivande • Nov 17
Nymox Pharmaceutical Corporation, Annual General Meeting, Dec 12, 2022 Nymox Pharmaceutical Corporation, Annual General Meeting, Dec 12, 2022, at 04:30 Eastern Daylight. Location: Margaritaville Resorts, Nassau Bahamas, Number Two Bay St Nasssau Bahamas Agenda: To receive the annual report of the directors, the financial statements of the corporation for the fiscal year ended December 31, 2021 and the auditors’ report thereon; to elect the directors of the corporation; to appoint the auditors of the corporation and to authorize the board of directors to fix their remuneration; to ratify the acts of the members of the board of directors for the fiscal year ending 2021; and, up and to the date of this meeting; to transact such other matters as may properly be brought before the meeting, or any adjournment thereof. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Lead Independent Director Rich Cutler was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jul 15
NYMOX Receives Deficiency Letter from NASDAQ Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reported that on July 7, 2022 the Company received a deficiency letter from NASDAQ stating that the Company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2). The Nasdaq letter states that the Company will be afforded 180 calendar days to regain compliance with the minimum bid price requirement. In order to regain compliance, the Company must have a closing bid price of $1.00 or more for a minimum of 10 consecutive business days. If at any time during this 180-day period the Company’s closing bid price meets or exceeds $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed. If the Company has not regained compliance by the expiration of the initial 180 calendar days, Nasdaq will then provide written notification to the Company that its ordinary shares are subject to delisting. At that time, the Company may appeal Nasdaq’s delisting determination to a Nasdaq Listing Qualifications Panel. Tillkännagivande • Jul 09
Nymox Pharmaceutical Corporation Announces Resignation of Erik Danielsen as Chief Financial Officer Nymox Pharmaceutical Corporation announced effective June 28, 2022, accepted the resignation of Erik Danielsen as Chief Financial Officer of the Company. Tillkännagivande • May 24
NYMOX Receives RTF letter from FDA Nymox Pharmaceutical Corporation received a Refusal to File letter from FDA on May 20 at 2:48 pm EST, with regard to the Company's New Drug Application (“NDA”) for Fexapotide Triflutate. Nymox’s position is that clarifications remain to be resolved at a follow-up meeting and that some significant inconsistencies were involved. The letter referred to a new outstanding issue of longer-term safety data and indicated that Nymox needed to have longer-term safety data in its NDA. Longer-term full safety data (as long as 6 years after a single low dose non-systemic injection given one time only) was not requested by the FDA in any previous pre-NDA communications. The Company's position is that Fexapotide safety profile is superior to any other conventional BPH treatment. 2. Fexapotide is a local injection with no detectable drug outside of prostate in patients after treatment. For a single injection (ie, given only one time) low dose local administration treatment, typical human clinical safety data duration requirements for approvals are in the few months range or less. Animal testing requirements are generally 2 weeks. 3. The FDA agreed at the end of Phase 2 that for eventual approval one-year safety data after a single injection of fexapotide 2.5 mg was adequate for Phase 3 pivotal studies, for clinical safety duration requirements. In Nymox pivotal Phase 3 trials 0017 and 0018, this data was achieved, and 12-month full safety data was provided in the NDA. The FDA provided detailed safety requests at the fexapotide pre-NDA meeting, which categorically did not include a longer-term clinical safety data request for fexapotide. 5. In addition, the NDA does include even longer-term (2-3 years) full safety data for fexapotide from n=344 subjects in Phase 3 Studies NX02-0020 and NX02-0022. There is no evidence of any long-term adverse safety outcomes in the pivotal study data for fexapotide. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Lead Independent Director Rich Cutler was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Mar 05
Nymox Pharmaceutical Corporation Announces Submission of New Drug Application to the FDA for Fexapotide Triflutate Nymox Pharmaceutical Corporation announced that it has submitted the Company’s New Drug Application (NDA) to the FDA for Fexapotide Triflutate to seek marketing approval in the U.S. for Fexapotide Triflutate for the treatment of men with benign prostatic hyperplasia (BPH). The submission of the application does not involve any guarantees or forward looking statements regarding outcomes of the submission. The Company will continue to make updates on all material and required developments with the application, and in accordance with prior statements provided in the Company’s regular SEC filings. Nymox intends to submit applications in other major markets in the near term and will provide updates at the appropriate times in due course. Tillkännagivande • Apr 29
Nymox Pharmaceutical Corporation announced that it expects to receive $7.999998 million in funding Nymox Pharmaceutical Corporation (NasdaqCM:NYMX) announced that it hsa entered in to definitive agreement for 3,669,724 shares at a price of $2.18 per share and warrants for the gross proceeds of $7,999,998.32? on April 28, 2021. Warrants issue in the transaction can be exercised in to 1,834,862 shares at a an exercise price of $2.50 per share and will expire five years from the date of issuance. The transaction is expected to close on or about April 30, 2021, subject to the satisfaction of customary closing conditions. The transaction is being made pursuant to the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D as promulgated by the United States Securities and Exchange Commission. Recent Insider Transactions • Apr 28
Independent Director recently bought US$83k worth of stock On the 22nd of April, James Robinson bought around 40k shares on-market at roughly US$2.08 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Mar 31
Full year 2020 earnings released: US$0.16 loss per share (vs US$0.19 loss in FY 2019) Full year 2020 results: Net loss: US$11.7m (loss narrowed 11% from FY 2019). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 11
New 90-day high: US$3.10 The company is up 52% from its price of US$2.04 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. Is New 90 Day High Low • Dec 19
New 90-day high: US$2.83 The company is up 16% from its price of US$2.43 on 18 September 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 17% over the same period. Is New 90 Day High Low • Dec 02
New 90-day low: US$1.84 The company is down 25% from its price of US$2.46 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 13% over the same period. Tillkännagivande • Nov 21
Nymox Pharmaceutical Corporation, Annual General Meeting, Dec 21, 2020 Nymox Pharmaceutical Corporation, Annual General Meeting, Dec 21, 2020, at 16:30 Eastern Daylight. Location: at the British Colonial Hilton, Nassau Bahamas, Number One Bay St Nassau Bahamas Agenda: To consider and receive the annual report of the directors, the financial statements of the corporation for the fiscal year ended December 31, 2019 and the auditors' report thereon; to consider to elect the directors of the corporation; to consider to appoint the auditors of the corporation and to authorize the board of directors to fix their remuneration; to ratify the acts of the members of the board of directors for the fiscal year ending 2019; and, up and to the date of this meeting; and to consider to transact such other matters as may properly be brought before the meeting, or any adjournment thereof. Is New 90 Day High Low • Oct 28
New 90-day low: US$2.07 The company is down 35% from its price of US$3.18 on 30 July 2020. The American market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. Is New 90 Day High Low • Oct 10
New 90-day low: US$2.20 The company is down 32% from its price of US$3.22 on 10 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. Is New 90 Day High Low • Sep 18
New 90-day low: US$2.37 The company is down 33% from its price of US$3.55 on 19 June 2020. The American market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. Tillkännagivande • Aug 17
Nymox Pharmaceutical Corporation has completed a Follow-on Equity Offering in the amount of $9 million. Nymox Pharmaceutical Corporation has completed a Follow-on Equity Offering in the amount of $9 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 3,600,000
Price\Range: $2.5
Discount Per Security: $0.175
Transaction Features: Registered Direct Offering